We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Pfizer raised its sales forecast for its Covid-19 vaccine by $2bn on Tuesday
US drugmaker’s coronavirus vaccine has almost doubled in price since its launch in 2020
Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections
US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic
US pharma group says RSV vaccine is 86% effective at preventing severe disease
Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials
US drugmaker and French partner begin late-stage trial with 14% of global population showing evidence of infection
Big Pharma group is using cash pile from sales of Covid-19 vaccines to replenish drug pipeline
Paxlovid dominates antiviral treatment market but weak demand could cause supply glut, data group says
US president has ‘very mild symptoms’ and is taking Pfizer antiviral pill
Competition and Markets Authority cuts £20mn from previous penalty after long legal battle
The latest strains have spread fast and governments are trying to catch up
Antiviral treatment Paxlovid is being widely prescribed despite questions about its effectiveness
New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain
US pharma group to pay €90.5mn for 8% in deal that will boost joint Lyme disease programme
US prepares to roll out jabs to last age group without access once regulatory approval is received
US pharma group to sell down stake in Haleon business after July IPO
Chief executive Albert Bourla launches plan to offer patented medicines at lower cost to poorer nations
Jabs for youngest children offer potential new market amid global glut of adult doses
Pharma group’s chief is right to take advantage of the market sell-off to boost pipeline
US pharmaceutical group’s biggest deal in more than 5 years comes as sales of its Covid vaccine are set to fall
Proxy advisers back shareholder resolutions as new shot shows promising results
Remuneration at the three big jab makers reflects surge in value of share options
International Edition